Multiple System Atrophy Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | H Lundbeck A/S, Brain Neurotherapy Bio, Asklepios BioPharmaceutical, Theravance Biopharma, Ono Pharmaceutical, Ionis Pharmaceutical

DelveInsight's "Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of MSA, historical and forecasted epidemiology, as well as the MSA market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover which therapies are expected to grab the Multiple System Atrophy Market Share @ Multiple System Atrophy Market Outlook- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Multiple System Atrophy Market Report
• In March 2025, Teva Branded Pharmaceutical Products R&D Inc., announced a study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286.
• In March 2025, Ono Pharmaceutical Co. Ltd conducted a study is to evaluate 3 doses of ONO-2808 compared to placebo in MSA patients, including: 1) safety and tolerability, 2) pharmacokinetics, and 3) changes in clinical outcome assessments (COA) and biomarkers considered to be related to the pharmacodynamics and potential efficacy of ONO-2808.
• In March 2025, Hoffmann-La Roche organized a study the safety and efficacy of RO7204239 in combination with risdiplam in patients with spinal muscular atrophy (SMA). The trial has two parts; Part 1 is the dose-finding part in SMA patients that are either ambulant (aged 2-10 years) or non-ambulant (aged 5-10 years) within separate cohorts, and Part 2 is the pivotal part in SMA patients aged 2-25 years that are ambulant.
• In March 2025, GeneCradle announced a trial is to evaluate safety and efficacy of gene therapy drug GC101 in SMA 2 patients. Open-label, dose-escalation clinical trial of GC101 will be conducted in multiple centers in China. GC101 will be administrated intrathecally. Short-term safety will be evaluated in 52 weeks and enter long-term follow-up study of 5 years at will. Patients will be tested at baseline and followed up on various time points.
• In March 2025, Dyne Therapeutics organized a study consists of 4 periods: A Screening Period (up to 8 weeks), a Placebo-Controlled Period (24 weeks), a Treatment Period (24 weeks) and a Long-Term Extension (LTE) Period (144 weeks) in both multiple-ascending dose (MAD) and dose expansion cohorts.
• In 2023, the US accounted for the highest prevalent cases of MSA with approximately 42,500 cases, which are expected to increase by 2034 at a CAGR of 1.0%.
• In 2023, the Germany reported the highest number of prevalent cases of MSA among the EU4 and the UK, with approximately 2,700 cases. UK followed with around 2,400 cases, while Spain recorded the lowest prevalent cases, with nearly 1,500 cases.
• In 2023, Japan reported approximately 5,100 prevalent cases of MSA in males and 12,000 cases in females, with numbers projected to rise by 2034.
• In the US, the number of cases in 2023 were as follows: around 400 cases in stage 0, around 800 in stage 1, ~2,100 in stage 2, ~15,000 in stage 3, ~13,000 in stage 4, and ~10,000 in stage 5 and these numbers projected to rise by 2034.
• In Japan, around 30% of MSA cases reported in 2023 were associated with MSA-P, while 70% were linked to MSA-C, indicating that MSA-C is the dominant type than MSA-P.
• In 2023, Germany recorded the highest number of MSA around 1,400 cases in the 70 years and above age group. Among the age groups 50-59 years and 60-79 years, the 70 years and above group is expected to see an increase to 1,500 cases by 2034.
• In 2023, Japan recorded around 13,700 cases of symptomatic nOH in MSA patients, with the number projected to reach around 14,100 cases by 2034.
• The leading Multiple System Atrophy Companies such as H Lundbeck A/S, Brain Neurotherapy Bio, Asklepios BioPharmaceutical, Theravance Biopharma, Ono Pharmaceutical, Ionis Pharmaceuticals, Biogen, Alterity Therapeutics, Teva Pharmaceutical, MODAG GmbH, and others.
• Promising Multiple System Atrophy Pipeline Therapies such as Lu AF82422, AAV2-GDNF Gene Therapy, Ampreloxetine (TD-9855), ONO-2808, ION464, ATH434, Emrusolmin, and others.

Stay ahead in the Multiple System Atrophy Therapeutics Market with DelveInsight's Strategic Report @ Multiple System Atrophy Market Outlook- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple System Atrophy Epidemiology Segmentation in the 7MM
• Multiple System Atrophy Diagnosed Prevalent Cases
• Multiple System Atrophy Gender-specific Diagnosed Prevalent Cases
• Multiple System Atrophy Age-specific Diagnosed Prevalent Cases
• Multiple System Atrophy Type-specific Diagnosed Prevalent Cases
• Multiple System Atrophy Stage-specific Diagnosed Prevalent Cases
• Multiple System Atrophy nOH Symptomatic Cases

Download the report to understand which factors are driving Multiple System Atrophy Epidemiology trends @ Multiple System Atrophy Prevalence- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple System Atrophy Emerging Drugs
• Emrusolmin (TEV-56286, Anle-138b): Teva Pharmaceutical/MODAG GmBH
Anle138b is a small molecule designed to target toxic alpha-synuclein oligomers, dissolving them and preventing new formations, thus addressing neurodegenerative disorders. Preclinical studies show it halts disease progression. Unlike antibody treatments, it is orally administered and crosses the blood-brain barrier.

• Amlenetug (Lu AF82422): H. Lundbeck A/S/Genmab
Lu AF82422 is a human monoclonal antibody designed to target toxic alpha-synuclein proteins involved in MSA pathology. It seeks to slow or stop disease progression by clearing these harmful proteins. The compound has demonstrated effectiveness in Phase II and has received orphan drug and SAKIGAKE designations. It is now in Phase III trials.

• Ampreloxetine (TD-9855): Theravance Biopharma
Ampreloxetine is an investigational norepinephrine reuptake inhibitor being developed for symptomatic neurogenic orthostatic hypotension (nOH) in MSA patients. It increases norepinephrine levels by blocking its transporters. Currently in Phase III trials, it has received ODD status from the US FDA and patent protection until 2037.

Multiple System Atrophy Treatment Market
MSA treatment primarily focuses on symptom management, as there is no cure. Pharmacological therapies, such as levodopa for Parkinsonism and other medications for autonomic dysfunction, cerebellar ataxia, and sleep disturbances, are commonly used. Immunotherapy is not typically part of MSA treatment, as it targets underlying protein aggregation rather than immune response. Emerging therapies include Amlenetug, Ampreloxetine, ATH434, TAK-341/MEDI1341 and Emrusolmin (Anle138b).

To learn more about Multiple System Atrophy treatment guidelines, visit @ Multiple System Atrophy Treatment Market Landscape- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple System Atrophy Market Outlook
MSA is a rare neurodegenerative disorder that typically begins in adulthood, usually after age 30. It shares symptoms with Parkinson's disease, such as Parkinsonism, but also includes additional features like cerebellar ataxia and autonomic dysfunction, affecting involuntary processes such as heart rate and blood pressure. MSA is classified as MSA-P when Parkinsonism predominates, and MSA-C when cerebellar symptoms are more prominent. Currently, no disease-modifying treatments are approved for MSA, offering a significant opportunity for pharmaceutical companies to develop the first effective therapies. Existing Parkinson's treatments like levodopa have limited effectiveness, underscoring the need for targeted treatments for MSA.

Scope of the Multiple System Atrophy Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Multiple System Atrophy Companies- H Lundbeck A/S, Brain Neurotherapy Bio, Asklepios BioPharmaceutical, Theravance Biopharma, Ono Pharmaceutical, Ionis Pharmaceuticals, Biogen, Alterity Therapeutics, Teva Pharmaceutical, MODAG GmbH, and others.
• Multiple System Atrophy Pipeline Therapies- Lu AF82422, AAV2-GDNF Gene Therapy, Ampreloxetine (TD-9855), ONO-2808, ION464, ATH434, Emrusolmin, and others.
• Multiple System Atrophy Market Dynamics: Multiple System Atrophy Market Drivers and Barriers
• Multiple System Atrophy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Multiple System Atrophy Drugs in development @ Multiple System Atrophy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Multiple System Atrophy Market Report Introduction
3. Multiple System Atrophy Market Overview at a Glance
4. Multiple System Atrophy Epidemiology and Market Forecast Methodology
5. Key Events
6. Multiple System Atrophy Executive Summary
7. Multiple System Atrophy Disease Background and Overview
8. Multiple System Atrophy Patient Journey
9. Multiple System Atrophy Epidemiology and Patient Population
10. Multiple System Atrophy Emerging Drugs
11. Multiple System Atrophy: Seven Major Market Analysis
13. KOL Opinion Leaders' Views
14. Multiple System Atrophy SWOT Analysis
15. Multiple System Atrophy Unmet Needs
16. Multiple System Atrophy Market Access and Reimbursement
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer

List of Top Selling Market Research Reports in 2025

Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.